NCT07388667

A Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002)

A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-4082 in Healthy Overweight/Obese Participants

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

Researchers are looking for new weight loss medicines for people with higher body weight. The study medicine, MK-4082, is different from similar weight loss medicines because people take it as a pill instead of an injection. Before giving a study medicine to people with a health condition, researchers first do studies to find a safe dose level (amount) of the study medicine that can be used in future studies. The goals of this study are to learn about: * The safety of MK-4082 and if people tolerate it * What happens to different MK-4082 dose levels in a person's body over time

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	MK-4082	Oral Tablet
DRUG	Placebo	Oral Tablet

Timeline

• Start date: 2026-03-04
• Primary completion: 2026-08-19
• Completion: 2026-08-19
• First posted: 2026-02-05
• Last updated: 2026-03-30

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study